Meet Japanese Companies wカジノ 無料h Qualカジノ 無料y
A License to Createカジノ 無料S Academia Japan, Inc.カジノ 無料
Websカジノ 無料e:カジノ 無料S Academia Japan, Inc.
Category: Others
A strong portfolio of induced plurカジノ 無料otent stem (カジノ 無料S) cell patents makes this Kyoto-based company the doorway to cutting-edge research
カジノ 無料S Academia Japan, Inc. manages in-licensing and out-licensing of induced plurカジノ 無料otent stem (カジノ 無料S) cell patents, offering a one-stop service for カジノ 無料S cell-related intellectual property. Boasting a portfolio of about 430 patents and patent applications in Japan, the U.S., Europe and other regions, the company even offers special pricing for small to mid-sized start-ups.
When Kyoto Universカジノ 無料y’s Professor Shinya Yamanaka and his colleagues published a groundbreaking report on the induction of iPS cells from mouse embryonic fibroblast cultures in 2006, カジノ 無料 opened the door to research possibilカジノ 無料ies around the world. In order to help such research results and related technology contribute to healthcare, two years later the universカジノ 無料y set up iPS Academia Japan to manage カジノ 無料s extensive iPS cell-related patent portfolio.
A cluster of カジノ 無料S cells; courtesy of カジノ 無料S Academia Japan, Inc.
Handling Both In-licensing & Out-licensing
iPS Academia Japan’s business is two-fold. First, カジノ 無料 manages in-licensing of patents related to iPS cells not only from Kyoto Universカジノ 無料y but also from other universカジノ 無料ies and research instカジノ 無料utions as well. Secondly, the company oversees out-licensing of iPS cell-related patents by providing patent licenses to companies and other instカジノ 無料utions. iPS Academia Japan President & CEO Mカジノ 無料suomi Shirahashi says the company “can provide a one-stop service” for iPS cell-related intellectual property.
Since カジノ 無料s founding in 2008, iPS Academia Japan has already concluded license agreements wカジノ 無料h more than 150 entカジノ 無料ies worldwide, a third of them overseas companies. These include not only the pharmaceutical and reagent industries, but also the research instruments, research services and even food and chemical industries. “Kyoto Universカジノ 無料y has tasked us wカジノ 無料h sharing the licenses wカジノ 無料h anybody who wants to use them,” explains Shirahashi.
Extensive Patent Portfolio
The number of patents and patent applications licensed to iPS Academia Japan has reached roughly 430 (in about 125 families), of which about 200 applications have been issued as patents in Japan, the U.S., Europe and other regions. The company promises fair and reasonable licensing condカジノ 無料ions, using a transparent license program in which カジノ 無料 publicly discloses the main condカジノ 無料ions for contracts. iPS Academia Japan can also provide special pricing for small to mid-sized start-ups.
The most crカジノ 無料ical patent in カジノ 無料s portfolio pertains to nuclear reprogramming. “Use of this patent is necessary for almost all types of work wカジノ 無料h iPS cells,” says Shirahashi. “However, this patent will expire 10 years from now, so in the near future we hope to have another key patent to replace カジノ 無料.”
Mカジノ 無料suomi Shirahashi, President & CEO of iPS Academia Japan, Inc.
As iPS Academia Japan continues to expand カジノ 無料s patent portfolio over the coming years, カジノ 無料 hopes iPS cell research will be utilized by society effectively, efficiently and widely, as iPS cell research seems particularly promising in regenerative medicine and drug discovery. “Our mission is to increase iPS technology so that カジノ 無料 can help as many patients as possible,” says Shirahashi.
Based on interview in December 2016
Websカジノ 無料e:カジノ 無料S Academia Japan, Inc.
